An update on antidepressant use and suicidality in pediatric depression

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 15, 2012, Pages 2119-2130

  Adegbite Adeniyi, Clara ^a   Gron, Brittany ^a   Rowles, Brieana M ^a   Demeter, Christine A ^a   Findling, Robert L ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Antidepressants; Children and adolescents; Depressive disorders; Suicidality

Indexed keywords

ANTIDEPRESSANT AGENT; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; CHILD; CHILD PSYCHIATRY; COGNITIVE THERAPY; DEPRESSION; DYSTHYMIA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GROUPS BY AGE; HUMAN; MAJOR DEPRESSION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS (TOPIC); MONOTHERAPY; OBSESSIVE COMPULSIVE DISORDER; PHYSICIAN; PRESCRIPTION; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; DEPRESSIVE DISORDER; DRUG LABELING; DRUG UTILIZATION; EUROPE; HUMANS; NORTH AMERICA; SEROTONIN UPTAKE INHIBITORS; SUICIDE;

EID: 84866495056     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.726613     Document Type: Review

References (72)

1. Medicines and Healthcare products Regulatory Agency. Paroxetine (Seroxat) - variation assessment report - proposal to contraindicate in adolescents and children under 18 years with major depressive disorder. 2003
2. European Agency for the Evaluation of Medicinal Products. European agency for the evaluation of medicinal products: committee for proprietary medicinal products. 2004;20-2
3. United States Food and Drug Administration. FDA statement regarding the anti-depressant Paxil for pediatric population. 2003
4. Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 2003;72:71-9 (Pubitemid 36302475)
5. United States Food and Drug Administration. Review and evaluation of clinical data: Relationship between psychotropic drugs and pediatric suicidality. 2004
6. Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007;164:1035-43 (Pubitemid 47121392)
7. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63:332-9 (Pubitemid 43345358)
8. Knesevich JW, Biggs JT, Clayton PJ, Ziegler VE. Validity of the hamilton rating scale for depression. Br J Psychiatry 1977;131:49-52 (Pubitemid 8136828)
9. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96
10. Davidson J, Turnbull CD, Strickland R, et al. The montgomery-asberg depression scale: reliability and validity. Acta Psychiatr Scand 1986;73:544-8 (Pubitemid 16091046)
11. Poznanski EO, Freeman LN, Mokros HB. Children's depression rating scale-revised. Psychopharmacol Bull 1985;21:979-89
12. Overholser JC, Brinkman DC, Lehnert KL, Ricciardi AM. Children's depression rating scale-revised: development of a short form. J Clin Child Psychol 1995;24:443-52 (Pubitemid 126002490)
13. Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 2009;66:633-9
14. Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007;164:884-91 (Pubitemid 46972903)
15. Wijlaars LPMM, Nazareth I, Petersen I. Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS ONE 2012;7:e33181
16. Zito JM, Safer DJ, dosReis S, et al. Rising prevalence of antidepressants among US youths. Pediatrics 2002;109:721-7 (Pubitemid 34493333)
17. Tournier M, Greenfield B, du Fort GG, et al. Patterns of antidepressant use in Quebec children and adolescents: trends and predictors. Psychiatry Res 2010;179:57-63
18. Skaer TL, Sclar DA, Robison LM. Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression. 1990 through 2001: an assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent Psychiatry. Clin Ther 2009;31:1478-87
19. Rushton JL, Whitmire JT. Whitmire, Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998. Arch Pediatr Adolesc Med 2001;155:560-5 (Pubitemid 32405779)
20. Olfson M, Marcus SC, Weissman MM, Jensen PS. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 2002;41:514-21 (Pubitemid 38338129)
21. Olfson M, Marcus SC, Druss BG. Effects of food and drug administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008;65:94-101
22. Mitchell B, Carleton B, Smith A, et al. Trends in psychostimulant and antidepressant use by children in 2 Canadian provinces. Can J Psychiatry 2008;53:152-9 (Pubitemid 351469374)
23. Ma J, Lee KV, Stafford RS. Depression treatment during outpatient visits by U.S. children and adolescents. J Adolesc Health 2005;37:434-42 (Pubitemid 41681764)
24. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 2006;163:1898-904 (Pubitemid 44807781)
25. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007;164:1356-63 (Pubitemid 47461135)
26. Delate T, Gelenberg AJ, Simmons VA, Motheral BR. Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002. Psychiatr Serv 2004;55:387-91 (Pubitemid 38445583)
27. Murray ML, Thompson M, Santosh PJ, Wong ICK. Effects of the committee on safety of medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Saf 2005;28:1151-7 (Pubitemid 41776005)
28. Murray ML, de Vries CS, Wong ICK. A drug utilisation study of antidepressants in children and adolescents using the general practice research database. Arch Dis Child 2004;89:1098-102
29. Middleton N, Gunnell D, Whitley E, et al. Secular trends in antidepressant prescribing in the UK, 1975-1998. J Public Health Med 2001;23:262-7 (Pubitemid 34087287)
30. Hsia Y, Maclennan K. Rise in psychotropic drug prescribing in children and adolescents during 1992-2001: a population-based study in the UK. Eur J Epidemiol 2009;24:211-16
31. Bergen H, Hawton K, Murphy E, et al. Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-olds. Br J Clin Pharmacol 2009;68:618-29
32. Foulon V, Svala A, Kowkinen H, et al. Impact of regulatory safety warnings on the use of antidepressants among children and adolescents in Finland. J Child Adolesc Psychopharmacol 2010;20:145-50
33. Fegert JM, Kolch M, Zito JM, et al. Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol 2006;16:197-206
34. Pamer CA, Hammad TA, Wu Y, et al. Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions. Pharmacoepidemiol Drug Saf 2010;19:158-74
35. Lineberry TW, Bostwick JM, Beebe TJ, Decker PA. Impact of the FDA black box warning on physician antidepressant prescribing and practice patterns: opening Pandora's suicide box. Mayo Clin Proc 2007;82:518-20 (Pubitemid 46543478)
36. Busch SH, Frank RG, Martin A, Barry CL. Characterizing declines in pediatric antidepressant use after new risk disclosures. Med Care Res Rev 2011;68:96-111
37. Valluri S, Zito JM, Safer DJ, et al. Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression. Med Care 2010;48:947-54
38. Kurian BT, Ray WA, Arbogast PG, et al. Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch Pediatr Adolesc Med 2007;161:690-6 (Pubitemid 47026329)
39. Bhatia SK, Rezac AJ, Vitiello B, et al. Antidepressant prescribing practices for the treatment of children and adolescents. J Child Adolesc Psychopharmacol 2008;18:70-80 (Pubitemid 351311243)
40. Singh T, Prakash A, Rais T, Kumari N. Decreased use of antidepressants in youth after us food and drug administration black box warning. Psychiatry (Edgmont) 2009;6:30-4
41. Busch SH, Frank RG, Leslie DL, et al. Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns? Psychiatr Serv 2010;61:11-16
42. Kurdyak PA, Juurlink DN, Mamdani MM. The effect of antidepressant warnings on prescribing trends in Ontario, Canada. Am J Public Health 2007;97:750-4
43. Volkers AC, Heerdink ER, van Dijk L. Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005). Pharmacoepidemiol Drug Saf 2007;16:1054-62 (Pubitemid 47422856)
44. United States Food and Drug Administration. Class suicidality labeling language for antidepressants. 2005
45. United States Food and Drug Administration. Reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD). 2003
46. Morrato EH, Libby AM, Orton HD, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2008;165:42-50 (Pubitemid 351704551)
47. Cheung A, Sacks D, Dewa CS, et al. Pediatric prescribing practices and the FDA Black-box warning on antidepressants. J Dev Behav Pediatr 2008;29:213-15
48. Windfuhr K, While D, Hunt I, et al. Suicide in juveniles and adolescents in the United Kingdom. J Child Psychol Psychiatry 2008;49:1155-65
49. Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003;60:978-82 (Pubitemid 37222079)
50. Centers for Disease Control and Prevention. Suicide trends among youths and young adults aged 10-24 years: United States, 1990-2004. MMWR Weekly 2007;56:905-8
51. Katz LY, Kozyrskyj AL, Prior HJ, et al. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ 2008;178:1005-11 (Pubitemid 351533190)
52. Wolitzky-Taylor KB, Ruggiero KJ, McCart MR, et al. Has adolescent suicidality decreased in the United States? Data from two national samples of adolescents interviewed in 1995 and 2005. J Clin Child Adolesc Psychol 2010;39:64-76
53. Emslie GJ, Rush J, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997;54:1031-7 (Pubitemid 27476099)
54. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002;41:1205-15 (Pubitemid 38338040)
55. Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry 2009;48:721-9
56. Wagner KD, Asarnow JA, Vitiello B, et al. Out of the black box: treatment of resistant depression in adolescents and the antidepressant controversy. J Child Adolesc Psychopharmacol 2012;22:5-10
57. Brent DA, Emslie GJ, Clarke GN, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry 2009;166:418-26
58. Vitiello B, Brent DA, Greenhill LL, et al. Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. J Am Acad Child Adolesc Psychiatry 2009;48:997-1004
59. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the scale for suicide ideation. J Consult Clin Psychol 1979;47:343-52 (Pubitemid 9157284)
60. Kaufman J, Birmaher B, Brent D, et al. Schedule for affective disorders and schizophrenia for school-age childrenpresent and lifetime version (K-SADSPL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36:980-8 (Pubitemid 27272932)
61. Reynolds WM, Mazza JJ. Assessment of suicidal ideation in inner-city children and adolescents: reliability and validity of the Suicidal Ideation Questionnaire-JR. School Psych Rev 1999;28:17-30
62. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-77
63. Vitiello B, Silva S, Rohde P, et al. Suicidal events in the Treatment for Adolescents with Depression Study (TADS). J Clin Psychiatry 2009;70:741-7
64. TADS Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 2004;292:807-20
65. Wilkinson P, Kelvin R, Roberts C, et al. Clinical and psychosocial predictors of suicide attempts and nonsuicidal self-injury in the Adolescent Depression Antidepressants and Psychotherapy Trial (ADAPT). Am J Psychiatry 2011;168:495-501
66. Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007;335:142
67. Brent DA, Greenhill LL, Compton S, et al. The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. J Am Acad Child Adolesc Psychiatry 2009;48:987-96
68. Brent D, Emslie G, Clark G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008;299:901-13 (Pubitemid 351397065)
69. Hughes CW, Emslie GJ, Crismon ML, et al. Texas children's medication algorithm project: update from texas consensus conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry 2007;46:667-86 (Pubitemid 46816821)
70. Gibbons RD, Brown CJ, Hur K, et al. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69:580-7
71. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007;297:1683-96
72. TADS Team. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007;64:1132-43